219 related articles for article (PubMed ID: 34240140)
1. The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma.
Peinado P; Andrades A; Martorell-Marugán J; Haswell JR; Slack FJ; Carmona-Sáez P; Medina PP
Hum Mol Genet; 2021 Nov; 30(23):2263-2271. PubMed ID: 34240140
[TBL] [Abstract][Full Text] [Related]
2. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
3. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
4. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
5. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
6. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
8. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
[TBL] [Abstract][Full Text] [Related]
9. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
10. SWI/SNF deficient central nervous system neoplasms.
Cai C
Semin Diagn Pathol; 2021 May; 38(3):167-174. PubMed ID: 33762087
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
12. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
13.
Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
[No Abstract] [Full Text] [Related]
14. Cdx2 Regulates Gene Expression through Recruitment of Brg1-associated Switch-Sucrose Non-fermentable (SWI-SNF) Chromatin Remodeling Activity.
Nguyen TT; Savory JGA; Brooke-Bisschop T; Ringuette R; Foley T; Hess BL; Mulatz KJ; Trinkle-Mulcahy L; Lohnes D
J Biol Chem; 2017 Feb; 292(8):3389-3399. PubMed ID: 28082674
[TBL] [Abstract][Full Text] [Related]
15. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
16. Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma.
Peinado P; Andrades A; Cuadros M; Rodriguez MI; Coira IF; Garcia DJ; Benitez-Cantos MS; Cano C; Zarzuela E; Muñoz J; Loidi C; Saiz M; Medina PP
Clin Epigenetics; 2022 Mar; 14(1):42. PubMed ID: 35300733
[TBL] [Abstract][Full Text] [Related]
17. Differential requirement of SWI/SNF for androgen receptor activity.
Marshall TW; Link KA; Petre-Draviam CE; Knudsen KE
J Biol Chem; 2003 Aug; 278(33):30605-13. PubMed ID: 12775722
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
20. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers.
Alver BH; Kim KH; Lu P; Wang X; Manchester HE; Wang W; Haswell JR; Park PJ; Roberts CW
Nat Commun; 2017 Mar; 8():14648. PubMed ID: 28262751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
